Molecular Hybrids of Thiazolidinone: Bridging Redox Modulation and Cancer Therapy
International Journal of Molecular Sciences · 07.07.2025 · 26 (13) · 6529
DOI: 10.3390/ijms26136529 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 07.07.2025. Verfasst von Nourah A Al Zahrani und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, College of Science, University of Jeddah, Jeddah 23218, Saudi Arabia. Hauptthemen laut MEDLINE: Thiazolidines, Antioxidants, Antineoplastic Agents, Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Heterocyclic compounds have shown that they hold significant therapeutic activities, highlighting the importance of discovering and developing novel candidates against cancers, infections, and oxidative stress-associated disorders. In this study, we demonstrated the biological activity of our previously synthesized thiazolidinone derivatives (TZDs-1, 6, and 7). Furthermore, we synthesized and structurally characterized a new derivative (TZD-5) using IR, 1H NMR, and 13C NMR spectroscopy, confirming the presence of its key functional groups, namely, carbonyl and imine. Their antioxidant activity was assessed through the DPPH assay, with TZD-5 showing the most potent effect (IC50 = 24.4 µg/mL), comparable to ascorbic acid, an effect attributed to the methoxy group introduced via N-alkylation. Cytotoxicity was evaluated using the MTS assay on normal (HFF-1) and cancerous (HepG2 and A549) cell lines at two time points: 24- and 48 h exposure. Our findings highlight clear differences in cytotoxicity and selectivity among the tested thiazolidinone derivatives. TZD-1 and TZD-6 demonstrated significant, dose-dependent cytotoxic effects on both cancerous (HepG2 and A549) and normal (HFF-1) cell lines, thus limiting their therapeutic potential due to insufficient selectivity. TZD-5 exhibited moderate selectivity with higher susceptibility for HepG2 cells compared to normal cells. Notably, TZD-7 showed the most favorable cytotoxic profile, demonstrating strong selective cytotoxicity toward cancer cell lines with minimal adverse effects on normal fibroblasts. Overall, the results highlight TZD-5 and TZD-7 as promising candidates for antioxidant and selective anticancer therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Chemistry, College of Science, University of Jeddah, Jeddah 23218, Saudi Arabia.
- Advanced Diagnostics and Therapeutics Institute, Health Sector, King Abdulaziz City for Science and Technology (KACST), Riyadh 11442, Saudi Arabia.
- Department of Biological Science, College of Science, University of Jeddah, Jeddah 23218, Saudi Arabia.
ORCID-Profile: Fahad A Almughem, Abdullah A Alshehri, Huda A Al-Ghamdi, Laila A Damiati
Zitieren
APA
Zahrani, N. A. A., Alshabibi, M. A., Bakr, A. A., Almughem, F. A., Alshehri, A. A., Al-Ghamdi, H. A., Tawfik, E. A., & Damiati, L. A. (2025). Molecular Hybrids of Thiazolidinone: Bridging Redox Modulation and Cancer Therapy. International Journal of Molecular Sciences, 26(13), 6529. https://doi.org/10.3390/ijms26136529
Vancouver
Zahrani NAA, Alshabibi MA, Bakr AA, Almughem FA, Alshehri AA, Al-Ghamdi HA, et al. Molecular Hybrids of Thiazolidinone: Bridging Redox Modulation and Cancer Therapy. International Journal of Molecular Sciences. 2025;26(13):6529. doi:10.3390/ijms26136529
BibTeX
@article{Zahrani2025,
author = {Zahrani, Nourah A Al and Alshabibi, Manal A and Bakr, Abrar A and Almughem, Fahad A and Alshehri, Abdullah A and Al-Ghamdi, Huda A and Tawfik, Essam A and Damiati, Laila A},
title = {Molecular Hybrids of Thiazolidinone: Bridging Redox Modulation and Cancer Therapy},
journal = {International Journal of Molecular Sciences},
year = {2025},
volume = {26},
number = {13},
pages = {6529},
doi = {10.3390/ijms26136529}
}
EUVIMED